A few years ago, The Longevity Centres of America proudly contributed to a study concerning the many benefits of IV chelation therapy – a treatment used to extract potentially harmful heavy metals from the bloodstream – for people suffering from heart conditions. Sponsored by the National Institutes of Health, the expansive clinical trial – named TACT for "Trial to Assess Chelation Therapy," the study was met with skepticism by some members of the medical community, but that may change now that the results have been released.

According to a press release from the American Heart Association, findings from the NIH-TACT were presented at the group's Scientific Sessions being held in Los Angeles this week. Over the course of the trial, 1,708 individuals who had survived a cardiac arrest were either given a total of 40 infusions of chelation liquid or a placebo via an IV.

The researchers reportedly found that the patients who received chelation treatments intravenously were less likely to experience another heart-related medical issue such as angina, stroke, an additional heart attack or death. This effect was reportedly greater among participants diagnosed with diabetes, but was still beneficial across the board.

"Although not approved by the Food and Drug Administration for treating heart disease, IV chelation therapy has been used for over 50 years," though it is often dismissed by "conventional medical practitioners," the release states that, though further research is necessary to confirm this effect, these undeniably positive results may cause skeptics to take a second look at this form at treatment.

Though it is unlikely that IV chelation will become a regular part of heart disease treatment in the near future, the anti-aging doctors at Longevity Centres of America have long been advocates for the health-related benefits of this detoxifying therapy.